Shionogi President Expects Strong Growth On Synergy Effect With Sciele
This article was originally published in PharmAsia News
Shionogi President Isao Teshirogi expects a strong growth after 2009 when a full synergy effect from acquiring U.S. company Sciele Pharma will take place. Teshirogi expressed the view at a Nov. 4 press briefing to announce interim results. The company has established a U.S. sales network through the ¥155 billion deal, and it also started operations in U.S. and European markets. Regarding U.S. clinic trials for Shionogi's obesity drug S-2367, Teshirogi commented that the results could be announced early next year. Teshirogi also touched upon recent rapid appreciation of yen, he said it is unlikely that the currency appreciation will help reduce research and development expenses in the U.S. (Click here for more - Japanese language
You may also be interested in...
Results from two trials confirm patients at high risk of bleeding treated with Abbott’s Xience stent can be safely treated with short regimens of dual antiplatelet therapy.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance hopes to build a potentially best-in-class presence in a competitive landscape.
An expert panel at the virtual HLTH conference discussed the role of robotics in improving health and wellness in the health continuum. See what Darla Hutton, vice president of US marketing and customer hospital analytics at Intuitive Surgical, said about the future of robotics.